Cantilever Investors logo
  • Home
  • About
  • Investor Network
  • Portfolio
  • Business partners
  • Contact

Acurx Announces All Patients Demonstrated Clinical and Sustained Cure in Ph2A Open-Label Trial of Ibezapolstat for Treatment of C. difficile Infection (CDI)

November 5, 2020

WHITE PLAINS, N.Y., Nov. 5, 2020 /PRNewswire/ -- Acurx Pharmaceuticals, LLC ("Acurx" or the "Company"), a privately held, clinical-stage biopharmaceutical company developing an entirely new class of antibiotics for difficult-to-treat bacterial infections, announced that all 10 patients (100%) with mild-to-moderate CDI enrolled in this Ph2A open-label clinical trial met the study's primary and secondary efficacy endpoints following treatment with orally administered ibezapolstat given 450 mg twice daily for 10 days. Continue Reading.

Previous post
All posts
Next post

Connect

© 2021 Cantilever Investors Powered by Jottful